OSR Health seeks Nasdaq delisting appeal hearing after staff determination

• OSR Holdings issued a CEO letter outlining an appeal plan following a Nasdaq Staff Delisting Determination received on Aug. 19.
• Formal request for a Nasdaq hearings panel review targeted for submission by Aug. 26.
• Reiterated a $15 million Put Option under the VXM01 license agreement, exercisable from Oct. 29 at $10 per share.
• Management cited ongoing talks with BCM Europe’s South Korean backers on settlement capacity; exercise date not expected to move earlier.
• Stated subsidiaries Woori IO and Darnatein will continue development activities despite listing uncertainty.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. OSR Holdings Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 202608211145ACCESSWRNAPR_____1210401) on August 21, 2026, and is solely responsible for the information contained therein.